Michael J. Droller
#167,475
Most Influential Person Now
Michael J. Droller's AcademicInfluence.com Rankings
Michael J. Drollerengineering Degrees
Engineering
#7468
World Rank
#8844
Historical Rank
Biomedical Engineering
#759
World Rank
#771
Historical Rank

Michael J. Drollerphilosophy Degrees
Philosophy
#9929
World Rank
#13559
Historical Rank
Logic
#6881
World Rank
#8439
Historical Rank

Download Badge
Engineering Philosophy
Michael J. Droller's Degrees
- Doctorate Medicine Stanford University
Why Is Michael J. Droller Influential?
(Suggest an Edit or Addition)Michael J. Droller's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. (2005) (421)
- Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. (2013) (372)
- A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. (2007) (300)
- A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. (2007) (277)
- Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial (1999) (271)
- The effect of age and gender on bladder cancer: a critical review of the literature (2010) (268)
- A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. (1978) (233)
- ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. (2013) (221)
- Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. (2000) (199)
- The natural history of bladder cancer. Implications for therapy. (2000) (192)
- Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. (2002) (185)
- Prevention of cyclophosphamide-induced hemorrhagic cystitis. (1982) (175)
- Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. (2005) (172)
- Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity (1998) (161)
- Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus (2014) (156)
- AN ELECTRON MICROSCOPE STUDY OF YOLK FORMATION DURING OOGENESIS IN LEBISTES RETICULATUS GUPPYI (1966) (133)
- Bladder cancer in the elderly. (2009) (128)
- New optical imaging technologies for bladder cancer: considerations and perspectives. (2012) (120)
- Bladder cancer: State‐of‐the‐art care (1998) (120)
- Advanced patient age is associated with inferior cancer‐specific survival after radical nephroureterectomy (2009) (116)
- Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. (1978) (106)
- An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer (2018) (88)
- C‐reactive protein is significantly associated with prostate‐specific antigen and metastatic disease in prostate cancer (2005) (84)
- Clinical and laboratory studies into the pathogenesis of malacoplakia. (1976) (76)
- Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? (2012) (75)
- Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms. (1993) (75)
- Urologic Oncology: Seminars and Original Investigations - Introduction (2003) (71)
- Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s) (2010) (69)
- Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. (2001) (63)
- In vitro enhancement of natural and antibody-dependent lymphocyte-mediated cytotoxicity against tumor target cells by interferon. (1979) (54)
- Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. (2006) (52)
- A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. (2002) (51)
- An approach to the control of massive hemorrhage in cyclophosphamide-induced cystitis by intravenous vasopressin: a case report. (1978) (50)
- Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. (2014) (49)
- Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. (2002) (47)
- Micropapillary bladder cancer: current treatment patterns and review of the literature. (2014) (46)
- Improved detection of recurrent bladder cancer using the bard BTA stat test. (1998) (46)
- Production of prostaglandin E2 by bladder tumor cells in tissue culture and a possible mechanism of lymphocyte inhibition. (1979) (45)
- Grading and staging of bladder carcinoma in transurethral resection specimens: correlation with 105 matched cystectomy specimens. (2000) (44)
- Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. (2002) (40)
- Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. (2000) (38)
- FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma (2004) (38)
- Molecular pathology of non-invasive urothelial carcinomas (part I) (2003) (36)
- A role for the macrophage in in vivo and in vitro resistance to murine bladder tumor cell growth. (1975) (33)
- The controversial role of radiation therapy as adjunctive treatment of bladder cancer. (1983) (33)
- Current concepts in assessment and treatment of bladder cancer (2000) (32)
- Surveillance and management of recurrence for upper tract transitional cell carcinoma. (2003) (32)
- Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? (2013) (31)
- Production of prostaglandin E2 by tumor cells in vitro. (1980) (28)
- Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. (2002) (27)
- THE ETIOLOGY OF BLADDER CANCER‐ARE THERE ANY NEW CLUES OR PREDICTORS OF BEHAVIOR? (1995) (26)
- Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid. (1987) (26)
- Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. (2002) (25)
- Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy. (2002) (25)
- Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide. (2000) (24)
- Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. (2002) (24)
- Thrombin-induced increase in intracellular cyclic 3',5'-adenosine monophosphate in human platelets. (1972) (24)
- Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid. (1982) (23)
- Bladder Cancer: Chemoprevention, complementary approaches and budgetary considerations (2008) (22)
- EDITORIAL: MARKERS IN BLADDER CANCER-ISSUES TO CONSIDER (1998) (22)
- Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe? (1985) (22)
- Bacillus Calmette-Guerin in the management of bladder cancer. (1986) (21)
- Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. (2002) (20)
- Medical approaches in the management of prostatic disease. (1997) (19)
- Assessing the quality of studies on the diagnostic accuracy of tumor markers. (2014) (19)
- Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines. (2003) (19)
- Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines. (1998) (19)
- Ultrastructure of the platelet release reaction in response to various aggregating agents and their inhibitors. (1973) (18)
- Current concepts of tumor markers in bladder cancer. (2002) (18)
- Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. (1997) (18)
- Ureteral Replacement Using Porcine Small Intestine Submucosa in a Porcine Model (2004) (17)
- Biological considerations in the assessment of urothelial cancer: a retrospective. (2005) (17)
- Ultrastructural visualization of the thrombin-induced platelet release reaction. (2009) (17)
- Urinary telomerase and its possible role as a marker for bladder cancer. (1998) (17)
- Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. (2016) (16)
- Urothelial cancer--mucosally confined disease can be aggressive. (2000) (15)
- Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. (2002) (15)
- Serum Androgen Levels in Healthy Premenopausal Women With and Without Sexual Dysfunction: Part A. Serum Androgen Levels in Women Aged 20–49 Years With No Complaints of Sexual Dysfunction (2004) (14)
- Muscle-invasive bladder cancer: does it arise de novo or from pre-existing superficial disease? (1989) (14)
- Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. (2016) (14)
- Lymphocyte and macrophage adenyl cyclase activity in animals with enhanced cell-mediated resistance to infection and tumors. (1975) (14)
- Markers in bladder cancer--issues to consider. (1998) (13)
- Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory). (2003) (13)
- Enhancement of natural cytotoxicity in lymphocytes from animals with carcinogen-induced bladder cancer. (1983) (12)
- Surgical Management of Urologic Disease: An Anatomic Approach (1992) (12)
- Interferon induction and prostaglandin synthetase inhibition in the in vitro and in vivo manipulation of immune response expression in an animal model of bladder cancer. (1982) (11)
- Therapeutic efficacy of salvage cystectomy. Do results reflect natural history of bladder cancer? (1983) (11)
- Prostaglandins and neoplasia. (1981) (11)
- Risk of continued intravesical therapy and delayed cystectomy in the BCG-refractory superficial bladder cancer: an investigational approach. (2002) (11)
- Lymphocyte-induced production of prostaglandin E2 by tumor cells in vitro: requirements for direct contact and lymphocyte viability. (1980) (11)
- Anatomic considerations in extraperitoneal approach to radical nephrectomy. (1990) (10)
- BLADDER, PENIS AND URETHRAL CANCER, AND BASIC PRINCIPLES OF ONCOLOGY (2001) (10)
- Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model. (1984) (10)
- It's a matter of time. (2011) (10)
- 264: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Carcinoma in Situ of the Urinary Bladder (2004) (10)
- Treatment of regionally advanced bladder cancer. An overview. (1992) (10)
- Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. (2002) (10)
- 263: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Stage TA/T1 Urothelial Cancer in the Urinary Bladder (2004) (9)
- Expression of the cellular immune response during tumor development in an animal model of bladder cancer. (1982) (9)
- Treatment modalities in superficial bladder cancer. (1989) (9)
- Biologic response modifiers in genitourinary neoplasia (1987) (9)
- Obstruction of ischemic ureteropelvic junction. (1974) (9)
- New Gleason grading system: Statement from the Editors of six journals. (2016) (9)
- Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. (2003) (9)
- Thiotepa effects on urinary cytology in the interpretation of transitional cell cancer. (1985) (8)
- Intracavitary bacillus Calmette-Guérin for Superficial Bladder Tumors. (2017) (8)
- Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. (2003) (8)
- Cancer patient advocacy: new opportunities for treatment advances. (2007) (8)
- A Systematic Overview of Radiation Therapy Effects in Urinary Bladder Cancer (2004) (8)
- Localization cytology in urothelial carcinoma. (1977) (7)
- WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. (1999) (7)
- Perspectives on prostate cancer diagnosis and treatment: a roundtable. (2001) (7)
- BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer. (2010) (7)
- Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. (2002) (7)
- Consensus guidelines for reporting prostate cancer Gleason Grade (2016) (7)
- Screening for bladder cancer: Theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease (2008) (7)
- Update on oncogenes and relevance in urology. (1987) (6)
- Premalignant Lesions and Carcinoma in situ in Bladder Neoplasia: Introduction and Overview (2000) (6)
- DD23 Biomarker. A Prospective Clinical Assessment in Routine Urinary Cytology Specimens From Patients Being Monitored for TCC (2004) (6)
- An electron microscope study of the time course of platelet nucleotide, calcium, and acid phosphatase secretion. (1974) (6)
- Uncertain role of cAMP in platelet function. (1972) (6)
- T1G3 Transitional Cell Carcinoma of the Bladder: Recurrence, Progression and Survival (2004) (6)
- Applications of telomerase in urologic oncology (2005) (6)
- Comprehensive handbook for developing a bladder cancer cystectomy database. (2013) (5)
- Environment and The Genitourinary Tract (1996) (5)
- Interferon: a perspective. (1980) (5)
- Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach (2020) (5)
- Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene. (2003) (4)
- Editorial: urothelial tumors--liberal applications of conservative approaches. (2003) (4)
- Thrombin-induced platelet prostaglandin and cyclic AMP production and a possible intrinsic modulation of platelet function. (2009) (4)
- 577 Photodynamic diagnosis of non-muscle invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis (2013) (4)
- Modulation of stimulatory effects of poly(I:C) on natural cytotoxicity by anti-interferon. (1984) (4)
- Editorial: Bladder Cancer (1994) (4)
- Primary care update on kidney and bladder cancer: a urologic perspective. (2004) (4)
- Prostaglandins and Expression of Lymphocyte Cytotoxicity (1985) (4)
- Immunohistochemical Analysis of NAD(P)H:Quinone Oxidoreductase and NADPH Cytochrome P450 Reductase in Human Superficial Bladder Tumours: Relationship Between Tumour Enzymology and Clinical Outcome Following Intravesical Mitomycin C Therapy (2004) (4)
- Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. (1998) (4)
- Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. (2001) (4)
- Bladder cancer: From pathogenesis to prevention (2008) (3)
- Bladder cancer. (1981) (3)
- Changing aspects in residency education. (2005) (3)
- Editorial: New Efforts to Stage Bladder Cancer (1995) (3)
- Nafarelin acetate and benign prostatic hyperplasia. (1988) (3)
- The natural history of invasive bladder cancer and the case against definitive radiation therapy (1985) (3)
- Controversies in urologic oncology. (1988) (3)
- Consensus guidelines for reporting prostate cancer Gleason Grade (2016) (3)
- A rose is a rose is a rose, or is it? (1986) (3)
- Stage Grouping. (2016) (3)
- Risk factors in clonal development from superficial to invasive bladder cancer. (1998) (3)
- Evolution of a Journal (2015) (2)
- Editorial Statement on Gleason Scoring for Prostate Cancer. (2016) (2)
- Macrophage depletion and manipulation of enhanced immune response in an animal model of bladder cancer. (1984) (2)
- Predictive Markers and Cancer Prevention. Urinary IL-2 Assay for Monitoring Intravesical Bacillus Calmette-Guérin Response of Superficial Bladder Cancer During Induction Course and Maintenance Therapy (2004) (2)
- Bacterial infection of renal calculus. (1977) (2)
- Bladder cancer: pebbles to reach the water. (1979) (2)
- Vigilance, vigilance, vigilance. (2010) (2)
- Re: Consensus Guidelines for Reporting Prostate Cancer (2016) (2)
- Evaluation and Management of Low-Grade, Low-Stage Bladder Cancer (2001) (2)
- Bladder cancer. (2020) (2)
- Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer. (2001) (2)
- New efforts to stage bladder cancer. (1995) (2)
- A new vision for clinical research. (2012) (2)
- Production of Prostaglandin E 2 by Tumor Cells in Vitro 1 (2006) (2)
- Immunotherapy and genitourinary neoplasia: An overview (1986) (1)
- Association of cyclooxygenase-2 expression with prognosis of state T1 grade 3 bladder cancer. (2003) (1)
- A guideline for discussion and some thoughts. (2009) (1)
- Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies (2000) (1)
- A Festschrift in Honor of Edward M. Messing, MD, FACS (2018) (1)
- Citizenship in our profession. (2010) (1)
- Differences in adenylate cyclase activities in murine normal cells and bladder tumor cells in tissue culture. (1976) (1)
- Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. (1998) (1)
- Markers for recurrence of superficial bladder cancer: what is valid? (2000) (1)
- A Model for 3-Dimensional Growth of Bladder Cancers to Investigate Cell-Matrix Interactions (2004) (1)
- Public education: the AUA and AUA foundation. (2005) (1)
- Distal ureteral regeneration after radical transurethral bladder tumor resection (2000) (1)
- Maintenance therapy for superficial bladder cancer. (2001) (1)
- Oncocytoma and metastatic potential: myth or reality? (1987) (1)
- A Commentary on Suramin Demonstrates in Vitro Toxicity against Transitional Cell Carcinoma Cell Lines and Exposure to Alkyllysophospholipids Inhibits in Vitro Invasion of Transitional Cell Carcinoma (1994) (1)
- Intravesical chemotherapy in the management of carcinoma in situ of the urinary bladder (1983) (1)
- PRINCIPLES OF ONCOLOGY AND IMMUNOLOGY, AND TUMORS OF BLADDER, PENIS AND URETHRA (2000) (1)
- Urologic Oncology: Seminars and Original Investigations. A Twenty-Fifth Anniversary History. (2021) (1)
- Superficial bladder disease: case studies and therapeutic advances. (1992) (1)
- Promoting surgeon-scientists in urologic oncology: The role of our journal. (2009) (1)
- Note by Editor (2007) (1)
- Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. (2003) (1)
- 25 years International Bladder Cancer Network (IBCN): The past, the present, and the future. (2022) (1)
- Standardization in pathologic assessment of transitional cell cancer of the bladder. (1998) (1)
- Editorial Comment: Extending the Domain of Minimally Invasive Surgery: Bladder Cancer (2001) (1)
- Effect of intravesical instillations on the human complement factor H related protein (BTA stat) Test. (2002) (1)
- The Management of Bladder Cancer (1988) (1)
- Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer. (2002) (0)
- Definitive radiation therapy and bladder cancer: do results reflect intrinsic tumor character? (1984) (0)
- Oncogenes and genitourinary neoplasia (1987) (0)
- Recent residency training programs in the USA : looking forward to the 21st century : シンポジウムII : 第50回東部総会 (1986) (0)
- Photosensitization treatment in bladder cancer. (1988) (0)
- [Bladder cancer: understanding the disease and future implications for assessment and therapy]. (2006) (0)
- Bladder Cancer: Principles of Combination Therapy. Edited by R.T.D.Oliver, W.F.Hendry and H.J.G.Bloom. Woburn, Massachusetts: Butterworths Publishers, Inc.1981. (1982) (0)
- Clinical and laboratory studies into the pathogenesis of malacoplakia Report of Cases CASE (0)
- Urologic cancer--when is less more? (2007) (0)
- This Month in Investigative Urology: Photosensitization Treatment in Bladder Cancer (1988) (0)
- Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma (2004) (0)
- Introduction to the 25th anniversary issue (2021) (0)
- Immunotherapy in genitourinary neoplasia. (1985) (0)
- Immuno peroxidase detection of carcino embryonic antigens and blood group substances in transitional cell carcinomas of the bladder (1981) (0)
- Chairmen's Summary (2008) (0)
- Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. (2003) (0)
- Bladder cancer: the power of study design, interpretation of data and clinical application. (1995) (0)
- Comparison of Telomerase Activity and Matrix Metalloproteinase-9 in Voided Urine and Bladder Wash Samples as a Useful Diagnostic Tool for Bladder Cancer (2004) (0)
- Seminar article Bladder cancer in the elderly (2009) (0)
- This month in Investigative Urology. A commentary on suramin demonstrates in vitro toxicity against transitional cell carcinoma cell lines and exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma. (1994) (0)
- The scope of urological interaction: Endless open sky (2011) (0)
- Ummunotherapy of metastatic renal cell carcinoma with polyonosinic-polycytidylic acid (1987) (0)
- Management and Prognosis of Transitional Cell Carcinoma Superficial Recurrence in Muscle-Invasive Bladder Cancer After Bladder Preservation (2004) (0)
- Legends in Urology. (2016) (0)
- Considerations in Immunotherapy of Genitourinary Neoplasia (1991) (0)
- Controversies in T1 bladder Ca: Early cystectomy vs. TUR (2003) (0)
- When is a cancer a malignancy? (2004) (0)
- Editorial Comment: Treatment of Advanced Bladder Cancer With Combined Preoperative Irradiation and Radical Cystectomy Versus Radical Cystectomy Alone (1997) (0)
- Editorial Comment: Diagnostic Accuracy of Urinary Cytology, and Deoxyribonucleic Acid Flow Cytometry and Cytology on Bladder Washings During Followup for Bladder Tumors (1997) (0)
- Prognostic value of p53 overexpression in T1G3 bladder tumours treated with bacillus Calmette-Guérin therapy. (2002) (0)
- Seminar article BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer 1 (2010) (0)
- To Accept or Not to Accept: Perspectives on Publication (2011) (0)
- WITHDRAWN: Introducing the Asian Journal of Urology (2014) (0)
- Editorial Comment: Transurethral Ultrasonographic Assessment of Bladder Carcinoma (1995) (0)
- Society of Urologic OncologyIntroduction (1999) (0)
- Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade: A. Zietman, E. Klein, M. J. Droller, P. Dasgupta, J. Catto and J. A. Smith, Jr. J Urol 2016; 195: 1723 (2016) (0)
- Atlas of Bladder Carcinoma (1986) (0)
- New steps forward for Urologic Oncology. (2013) (0)
- A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. (2000) (0)
- Commentary (Droller): Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer (2002) (0)
- In Reply to Samaratunga et al. (2016) (0)
- A history of the Society of Urologic Oncology. (2021) (0)
- Chapter 17 – Diagnosis and Staging of Bladder Cancer (2005) (0)
- A Tribute to Allen: Patient Needs and Options in Health Care. (2022) (0)
- Photodynamic Therapy for Refractory Superficial Bladder Cancer: Long-Term Clinical Outcomes of Single Treatment Using Intravesical Diffusion Medium (2004) (0)
- Invasive transitional cell cancer in the elderly (2007) (0)
- UROLOGICAL SURVEY: ABSTRACTSUrological Oncology: Bladder, Penis and Urethra Cancer, and Basic Principles of Oncology (2003) (0)
- Therapy and Prophylaxis of Superficial Bladder CarcinomasHulandH. and KlosterhalfenH.: New York: Thieme-Stratton, Inc.1985: 112. 53 figures, 47 tables. (1986) (0)
- 1293 A META-ANALYSIS OF BLUE LIGHT CYSTOSCOPY WITH HEXAMINOLEVULINATE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (2013) (0)
- Bladder Cancer. Edited by P.H.Smith and G.R.Prout. London: Butterworth, Inc.1984: 275. 78 figures, 53 tables. (1985) (0)
- Peer review of guidelines, best practice statements and new documents: what this means for how we use them. (2008) (0)
- Phase I Study of Gemcitabine and Radiotherapy Plus Cisplatin After Transurethral Resection as Conservative Treatment for Infiltrating Bladder Cancer (2004) (0)
- Introducing the Asian Journal of Urology (2014) (0)
- Reproductive infertility microsurgery in the male and female. Sherman J. Silber, 418pp, Williams and Wilkins, Baltimore, MD, 1984, $58.95 (1985) (0)
- , H. Huland, H. Klosterhalfen. Thieme-Stratton, Inc., New York (1985), 112, 53 figures, 47 tables (1986) (0)
- Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. (2016) (0)
- Editorial Comment: Lymphatogenous Spread of Renal Cell Carcinoma (1997) (0)
- Preface urologic issues for the internist. (2011) (0)
- Letter from the Editor, “Thank you”, Michael J. Droller, M.D. (2020) (0)
- George Russell Prout Jr., M.D., 1924-2013, founding editor, urologic oncology. (2014) (0)
- UROLOGY FOUNDED IN 1917 BY HUGH HAMPTON YOUN G (1990) (0)
- Evaluation of the clinical value of urinary NMP22 as a marker for screening and surveillance of transitional cell carcinoma of the urinary bladder. (2002) (0)
- Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. (2002) (0)
- Bladder cancer. (1997) (0)
- Bladder cancer. (1994) (0)
- Inhibition of Tumor Growth in Association with Modification of in Vivo Immune Response by Indomethacin and Polyinosinic:Polycytidylic Acid1 (2006) (0)
- Comprar Urologic issues for the Internist, An Issue of Medical Clinics of North America | Michael J. Droller | 9781437724660 | Saunders (2010) (0)
- We need to lead and not be led. (2006) (0)
- An editor's considerations in publishing industry-sponsored studies. (2015) (0)
- Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. (2006) (0)
- , R.T.D. Oliver, W.F. Hendry, H.J.G. Bloom (Eds.). Butterworths Publishers, Inc., Woburn, Massachusetts (1981) (1982) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael J. Droller?
Michael J. Droller is affiliated with the following schools: